Results 71 to 80 of about 8,771 (219)

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks

Frontiers in Immunology
BackgroundAtopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced by cytokines dependent on Janus kinases (JAKs).
Teppei Hagino, Risa Hamada, Mai Yoshida, Eita Fujimoto, Hidehisa Saeki, Naoko Kanda   +5 more
doaj   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2023
Wenting Hu, Si Zhang, Cuihong Lian Department of Dermatology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Cuihong Lian, Department of Dermatology, Shenzhen Second People’s Hospital, No.
Hu W, Zhang S, Lian C
doaj  

Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study [PDF]

Atopic dermatitis (AD) is the most common inflammatory skin disease often associated with comorbidities, including allergic rhinitis (AR; 40.3% of patients) and allergic asthma (AA; 51.3%).1 Among systemic treatments approved for severe AD, dupilumab
Amoruso, F, Balato, A, Barei, F, Bertello, M, Burroni, A G, Caccavale, S, Costanzo, A, Ferrucci, S M, Foti, C, Gaiani, F M, Gargiulo, L, Girolomoni, G, Guanti, M B, Ibba, L, Malagoli, P, Marzano, A V, Maurelli, M, Napolitano, M, Narcisi, A, Nettis, E, Ortoncelli, M, Patruno, C, Pezzolo, E, Piscazzi, F, Ribero, S, Romita, P, Rossi, M T, Zaza, I   +27 more
core   +1 more source

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor‐Modulating Agent in the Treatment of Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji, Yoko Fuyuno, Koji Kawamura, Ayako Yumine, Masaki Takemura, Yasutaka Mitamura, Kazuhiko Yamamura, Takeshi Nakahara   +7 more
wiley   +1 more source

Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

Drug Design, Development and Therapy, 2021
Meng-Jie Wang,1 Yu-Hang Zhao,2 Chen Fan,3 Ying-Jie Wang,3 Xin-Qi Wang,3 Xiang-Jun Qiu,3 Rui-Le Shen1 1Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan ...
Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ, Shen RL   +6 more
doaj  

Efficacy and safety of upadacitinib in the treatment of recalcitrant vitiligo [PDF]

Background: Vitiligo is an acquired autoimmune disease resulting in depigmented patches of the skin, often leading to a significant psychosocial burden on patients. Building on recent advancements in understanding the immunological mechanisms in vitiligo
Dash, Pranam Swapan, Hasan, M. Kamrul, Khan, M. Alauddin, Khondker, Lubna, Nabila, Noshin, Nasrin, Tanjina, Nath, Pankaj Kanti   +6 more
core   +2 more sources

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Research & Therapy
Background In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel   +13 more
doaj   +1 more source

Role of Janus kinase Inhibitors (JAKis) in Autoimmune Disorders: Review [PDF]

JAK inhibitors (JAKis) comprise a crucial therapeutic tool for managing patients with immune-mediated inflammatory disorders. Although often perceived as a uniform class of medications thought to be largely interchangeable, notable variances exist in ...
H. Shehata, Lamia, M. Nasr, Mohamed, Naser, Maged   +2 more
core   +2 more sources